Intranasal complications in women with osteoporosis under treatment with nasal calcitonin spray: Case reports and review of the literature

Auris Nasus Larynx

Volumn 35, Issue 3, 2008, Pages 417-422

  Chatziavramidis, Angelos ^a   Mantsopoulos, Konstantinos ^a   Gennadiou, Dimosthenis ^a   Sidiras, Thomas ^b  

^a General Hospital of Giannitsa   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Calcitonin; Nasal septum; Osteoporosis; Side effects; Synechiae

Indexed keywords

CALCITONIN; DEXPANTHENOL; PSEUDOMONIC ACID;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MEDICAL LITERATURE; MEDLINE; NOSE DISEASE; NOSE SEPTUM PERFORATION; NOSE SYNECHIA; PATIENT REFERRAL; POSTMENOPAUSE OSTEOPOROSIS; SEPTUM CONCHA INFERIOR SYNECHIAE; SYMPTOM; TREATMENT DURATION;

ADMINISTRATION, INTRANASAL; AGED; CALCITONIN; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY; EPISTAXIS; FEMALE; HUMANS; MIDDLE AGED; NASAL MUCOSA; NASAL SEPTUM; NOSE DISEASES; OSTEOPOROSIS, POSTMENOPAUSAL; TURBINATES;

EID: 47749117550     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2007.08.004     Document Type: Article

References (21)

1. Silverman S. Calcitonin. Clin Geriatr Med 19 (2003) 381-394
2. Pontiroli A.E., Pajetta E., Scaglia L., Rubinacci A., Resmini G., Arrigoni M., et al. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study. Aging 6 (1994) 459-463
3. Plosker G.L., and McTavish D. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8 (1996) 378-400
4. DiGeorge A.M., and LaFranchi S. Disorders of the parathyroid glands. In: Nelson W.E., Behrman R.E., Kliegman R.M., et al. (Eds). Nelson textbook of pediatrics. 15th ed. (1996), WB Saunders, Philadelphia 1605-1612
5. Pisati P., Feletti F., De Bernardi M., Tripodi A.S., Contos S., Germogli R., et al. Intranasal absorption of various calcitonin spray preparations. Boll Chim Farm 131 (1992) 120-127
6. Bragga P.C., Piatti G., Dal Sasso M., and Bermini A. The effects of calcitonin nasal preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test. J Pharm Pharmacol 44 (1992) 938-940
7. Verse T., Sikora C., Rudolph P., and Klφcker. The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters. Laryngo-Rhino-Otol 82 (2003) 782-789
8. Silverman S. Calcitonin. Endocrinol Metab Clin North Am 32 (2003) 273-284
9. Silverman S., and Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13 (2002) 858-867
10. Adachi J.D., Bensen W.G., Bell M.J., Bianchi F.A., Cividino A.A., Craig G.L., et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36 (1997) 255-259
11. Clissold S.P., Fitton A., and Chrisp P. Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1 (1991) 405-423
12. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., et al. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur J Pharm Sci 13 (2001) 179-185
13. Pontiroli A.E., Pajetta E., Calderara A., Alberetto M., Pozza G., Manganelli V., et al. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study. J Endocrinol Invest 14 (1991) 47-51
14. Honda N., Saito H., Yamada T., and Noda I. Basic study on the effect of nasally administered salmon calcitonin preparation on the nasal ciliary epithelium. Auris Nasus Larynx 19 (1992) 115-123
15. Gariboldi L.M., Bolla I., Baroni M.C., Delsignore R., Passeri M., and Barberis F. Long-term local tolerability to intranasally administered salmon calcitonin in post-menopausal osteoporosis. Minerva Med 83 (1992) 827-831
16. Reginster J.Y., and Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 3 (1985) 155-157
17. Pocel S.L., Cumplido J.A., de la Hoz B., Cuevas M., and Losada E. Anaphylaxis to calcitonin. Allergol Immunopathol (Madr) 28 (2000) 243-245
18. Reginster J.Y., Gaspar S., Deroisy R., Zegels B., and Franchimont P. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation. Osteoporos Int 3 (1993) 261-264
19. Di Perri T., Laghi Pasini F., Capecchi P.L., Blardi P., Pasqui A.L., Franchi M., et al. Pharmacodynamics of salmon calcitonin in humans: new markers of pharmacological activity. Eur J Clin Pharmacol 43 (1992) 229-233
20. Thamsborg G., Moller T., Kolerup G., and Sorensen O.H. Lack of effect of nasal salmon calcitonin on cell-mediated immunity. Bone Miner 20 (1993) 245-249
21. Lacroix J.S. Chronic rhinosinusitis and neuropeptides. Swiss med wkly 133 (2003) 560-562